Kenya’s life sciences sector encompasses healthcare services, pharmaceutical manufacturing, medical devices, biotechnology, and health data analytics. It is attracting increasing interest from international investors.
Investment Structures
Private hospitals and healthcare facilities can be structured as Kenyan private limited companies with foreign shareholders, subject to sector-specific restrictions. The PPP framework under the Public Private Partnerships Act 2021 provides a mechanism for investor-government partnerships in health facility development and operation.
Biotechnology and GMO Regulation
Biotechnology activities, including genetic research and GMO product development, are regulated by the National Biosafety Authority under the Biosafety Act 2009. Research involving GMOs requires NBA approval. The regulatory environment for GMO crop cultivation has been subject to policy changes.
Health Data and Research Governance
Research involving human subjects and health data is subject to the DPA 2019 for personal data, NACOSTI requirements, and ethics review requirements. Genomic data raises significant privacy and consent issues requiring robust governance frameworks.
Intellectual Property in Life Sciences
Patents are the primary IP protection mechanism for pharmaceutical and biotechnology innovations under the Industrial Property Act 2001. Kenya, as an LDC for WTO purposes, has access to certain TRIPS flexibilities for pharmaceutical patents, though the extent of domestic implementation requires specific legal analysis.
Investing in Kenya’s life sciences sector? Contact Clay & Associates Advocates for specialist advice. Book a Consultation
